At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients.
Our Programs
![KRAS](https://www.mirati.com/wp-content/uploads/callout_kras-inhibitors.png)
KRAS
Our scientists are rigorously advancing research and development programs targeting the KRASG12C and KRASG12D mutations.
![MRTX1719](https://www.mirati.com/wp-content/uploads/callout_program_prmt5@2x.png)
MRTX1719
MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.
Mirati is developing a pipeline of novel therapeutics.
![](https://www.mirati.com/wp-content/uploads/graphic_m_2x.png)
Become part of something bigger.
Error: Failed to decode JSON.